{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:20:27Z","timestamp":1790230827614,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81102504"],"award-info":[{"award-number":["81102504"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81202586"],"award-info":[{"award-number":["81202586"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"National High-Tech Program of China","doi-asserted-by":"publisher","award":["2012AA020306"],"award-info":[{"award-number":["2012AA020306"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Natural Science Foundation of Chin","award":["BS2013YY054"],"award-info":[{"award-number":["BS2013YY054"]}]},{"name":"Shandong Natural Science Foundation of Chin","award":["ZR2010HL023"],"award-info":[{"award-number":["ZR2010HL023"]}]},{"name":"Intramural Research Program of the Center for Cancer Research"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health (1ZIABC005562-24)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.bcp.2014.05.001","type":"journal-article","created":{"date-parts":[[2014,5,10]],"date-time":"2014-05-10T02:35:48Z","timestamp":1399689348000},"page":"166-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Metabolic profiling of praziquantel enantiomers"],"prefix":"10.1016","volume":"90","author":[{"given":"Haina","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Ze","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher W.","family":"Krausz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dequn","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Idle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2014.05.001_bib0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7257\/1053-816X.2013.33.4.163","article-title":"Schistosomiasis","volume":"33","author":"Jenkins-Holick","year":"2013","journal-title":"Urol Nurs"},{"key":"10.1016\/j.bcp.2014.05.001_bib0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pt.2003.11.010","article-title":"Schistosomiasis control: keep taking the tablets","volume":"20","author":"Hagan","year":"2004","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.bcp.2014.05.001_bib0015","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1371\/journal.pntd.0000504","article-title":"Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni","volume":"3","author":"Melman","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bcp.2014.05.001_bib0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2133\/dmpk.DMPK-10-RG-041","article-title":"Metabolite profiling of praziquantel and its analogs during the analysis of in vitro metabolic stability using information-dependent acquisition on a hybrid triple quadrupole linear ion trap mass spectrometer","volume":"25","author":"Huang","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.bcp.2014.05.001_bib0025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0731-7085(01)00417-4","article-title":"Investigation of praziquantel metabolism in isolated rat hepatocytes","volume":"26","author":"Meier","year":"2001","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.bcp.2014.05.001_bib0030","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0006-2952(94)90464-2","article-title":"Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors","volume":"48","author":"Masimirembwa","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.001_bib0035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00228-003-0636-9","article-title":"Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data","volume":"59","author":"Li","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.001_bib0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1067\/mcp.2002.129319","article-title":"Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers","volume":"72","author":"Ridtitid","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2014.05.001_bib0045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2710.2007.00862.x","article-title":"Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers","volume":"32","author":"Ridtitid","year":"2007","journal-title":"J Clin Pharm Therapeut"},{"key":"10.1016\/j.bcp.2014.05.001_bib0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4269\/ajtmh.1991.45.345","article-title":"Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica","volume":"45","author":"Wu","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.bcp.2014.05.001_bib0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/infdis\/159.3.589","article-title":"Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni","volume":"159","author":"Xiao","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2014.05.001_bib0060","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/BF00931694","article-title":"Light and scanning electron microscopy studies on the effects of the enantiomers of praziquantel and its main metabolite on Schistosoma mansoni in vitro","volume":"78","author":"Staudt","year":"1992","journal-title":"Parasitol Res"},{"key":"10.1016\/j.bcp.2014.05.001_bib0065","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1016\/j.jchromb.2009.07.036","article-title":"Enantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC\u2013MS\/MS: application to pharmacokinetics","volume":"877","author":"Lima","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.bcp.2014.05.001_bib0070","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.bcp.2011.01.024","article-title":"A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC\u2013ESI-QTOFMS-based metabolomics","volume":"81","author":"Li","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.001_bib0075","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1021\/tx0600402","article-title":"A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse","volume":"19","author":"Giri","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bcp.2014.05.001_bib0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev-pharmtox-010611-134748","article-title":"Xenobiotic metabolomics: major impact on the metabolome","volume":"52","author":"Johnson","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bcp.2014.05.001_bib0085","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1476-5381.2012.02067.x","article-title":"Metabolic map and bioactivation of the anti-tumour drug noscapine","volume":"167","author":"Fang","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.001_bib0090","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1021\/tx200033v","article-title":"Profiling the reactive metabolites of xenobiotics using metabolomic technologies","volume":"24","author":"Li","year":"2011","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bcp.2014.05.001_bib0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2125.2009.03572.x","article-title":"Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction","volume":"69","author":"Fang","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.001_bib0100","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/j.1875-9114.1995.tb02863.x","article-title":"Stereochemical aspects of pharmacotherapy","volume":"15","author":"Brocks","year":"1995","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bcp.2014.05.001_bib0105","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/bdd.517","article-title":"Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics","volume":"27","author":"Brocks","year":"2006","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.bcp.2014.05.001_bib0110","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00228-010-0792-7","article-title":"Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies","volume":"66","author":"Torrado","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2014.05.001_bib0115","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1021\/ac203291d","article-title":"Chiral metabonomics: 1H NMR-based enantiospecific differentiation of metabolites in human urine via direct cosolvation with beta-cyclodextrin","volume":"84","author":"Perez-Trujillo","year":"2012","journal-title":"Anal Chem"},{"key":"10.1016\/j.bcp.2014.05.001_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-022X(02)00124-0","article-title":"The importance of stereoselective determination of drugs in the clinical laboratory","volume":"54","author":"Rentsch","year":"2002","journal-title":"J Biochem Biophys Methods"},{"key":"10.1016\/j.bcp.2014.05.001_bib0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1517\/17425255.3.2.149","article-title":"Stereoselectivity in drug metabolism","volume":"3","author":"Lu","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.bcp.2014.05.001_bib0130","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jps.2600780902","article-title":"Enantioselective aspects of drug action and disposition: therapeutic pitfalls","volume":"78","author":"Jamali","year":"1989","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bcp.2014.05.001_bib0135","doi-asserted-by":"crossref","first-page":"760","DOI":"10.2174\/156802611795165098","article-title":"The significance of chirality in drug design and development","volume":"11","author":"Brooks","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bcp.2014.05.001_bib0140","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.bmcl.2010.03.001","article-title":"Praziquantel analogs with activity against juvenile Schistosoma mansoni","volume":"20","author":"Dong","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bcp.2014.05.001_bib0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0163-7258(85)90020-8","article-title":"Praziquantel: mechanisms of anti schistosomal activity","volume":"29","author":"Andrews","year":"1985","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bcp.2014.05.001_bib0150","first-page":"593","article-title":"Levo-praziquantel versus praziquantel in experimental and clinical treatment of Schistosomiases japonica","volume":"106","author":"Liu","year":"2005","journal-title":"Chin Med J"},{"key":"10.1016\/j.bcp.2014.05.001_bib0155","first-page":"935","article-title":"Comparative efficacy of praziquantel and its optic isomers in experimental therapy of Schistosomiasis japonica in rabbits","volume":"99","author":"Liu","year":"1986","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.bcp.2014.05.001_bib0160","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1371\/journal.pntd.0000357","article-title":"Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment","volume":"3","author":"Meyer","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bcp.2014.05.001_bib0165","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1002\/jps.10475","article-title":"Inhibition of the rat hepatic microsomal flurbiprofen acyl glucuronidation by bile acids","volume":"92","author":"Mano","year":"2003","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bcp.2014.05.001_bib0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/chir.10227","article-title":"Stereoselective pharmacokinetics of flurbiprofen and formation of covalent adducts with plasma protein in adjuvant-induced arthritic rats","volume":"15","author":"Nagao","year":"2003","journal-title":"Chirality"},{"key":"10.1016\/j.bcp.2014.05.001_bib0175","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1124\/dmd.109.028944","article-title":"Glucuronidation and covalent protein binding of benoxaprofen and flunoxaprofen in sandwich-cultured rat and human hepatocytes","volume":"37","author":"Dong","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2014.05.001_bib0180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0009-2797(03)00020-6","article-title":"Acyl glucuronide reactivity in perspective: biological consequences","volume":"145","author":"Bailey","year":"2003","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.bcp.2014.05.001_bib0185","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/j.1875-9114.1982.tb03212.x","article-title":"Pharmacology, clinical efficacy, and adverse effects of the nonsteroidal anti-inflammatory agent benoxaprofen","volume":"2","author":"Dahl","year":"1982","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bcp.2014.05.001_bib0190","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1124\/dmd.110.034173","article-title":"Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide","volume":"38","author":"Sawamura","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2014.05.001_bib0195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.seizure.2009.12.004","article-title":"Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy","volume":"19","author":"Sanchez","year":"2010","journal-title":"Seizure: J Brit Epilepsy Assoc"},{"key":"10.1016\/j.bcp.2014.05.001_bib0200","first-page":"8443","article-title":"Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives","volume":"63","author":"Cummings","year":"2003","journal-title":"Cancer Res"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214002615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214002615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T06:36:22Z","timestamp":1565418982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295214002615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0006295214002615"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2014.05.001","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic profiling of praziquantel enantiomers","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2014.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}